Standard
Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1. / Ahrén, B; Adner, N; Svartberg, J; Petrella, E; Holst, Jens Juul; Gutniak, M K.
In:
Diabetic Medicine, Vol. 19, No. 9, 09.2002, p. 790-2.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Ahrén, B, Adner, N, Svartberg, J, Petrella, E, Holst, JJ & Gutniak, MK 2002, 'Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1', Diabetic Medicine, vol. 19, no. 9, pp. 790-2.
APA
Ahrén, B., Adner, N., Svartberg, J., Petrella, E., Holst, J. J., & Gutniak, M. K. (2002). Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1. Diabetic Medicine, 19(9), 790-2.
Vancouver
Ahrén B, Adner N, Svartberg J, Petrella E, Holst JJ, Gutniak MK. Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1. Diabetic Medicine. 2002 Sep;19(9):790-2.
Author
Ahrén, B ; Adner, N ; Svartberg, J ; Petrella, E ; Holst, Jens Juul ; Gutniak, M K. / Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1. In: Diabetic Medicine. 2002 ; Vol. 19, No. 9. pp. 790-2.
Bibtex
@article{db3230bc54a24d24827b4e5c5ed31e2b,
title = "Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1",
keywords = "Adult, Amyloid, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glucagon, Glucagon-Like Peptide 1, Humans, Hyperglycemia, Hypoglycemic Agents, Islet Amyloid Polypeptide, Male, Peptide Fragments, Protein Precursors",
author = "B Ahr{\'e}n and N Adner and J Svartberg and E Petrella and Holst, {Jens Juul} and Gutniak, {M K}",
year = "2002",
month = sep,
language = "English",
volume = "19",
pages = "790--2",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "9",
}
RIS
TY - JOUR
T1 - Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1
AU - Ahrén, B
AU - Adner, N
AU - Svartberg, J
AU - Petrella, E
AU - Holst, Jens Juul
AU - Gutniak, M K
PY - 2002/9
Y1 - 2002/9
KW - Adult
KW - Amyloid
KW - Blood Glucose
KW - Diabetes Mellitus, Type 1
KW - Female
KW - Glucagon
KW - Glucagon-Like Peptide 1
KW - Humans
KW - Hyperglycemia
KW - Hypoglycemic Agents
KW - Islet Amyloid Polypeptide
KW - Male
KW - Peptide Fragments
KW - Protein Precursors
M3 - Journal article
C2 - 12207819
VL - 19
SP - 790
EP - 792
JO - Diabetic Medicine
JF - Diabetic Medicine
SN - 0742-3071
IS - 9
ER -
